Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHERBOC
2017-000565-76Phase 2Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Seribantumab + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started Sep 2017; status: terminated.
02
Drugs
seribantumabfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-000565-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000565-76.